News | July 19, 2021
Lonza extends collaboration with Biopharma company
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
